Podcast Episode
View More
Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
Hear Philip N. Newsome, PhD, FRCPE, discuss the agents in late-phase clinical trials and their potential use in the treatment of NASH and fibrosis, including those in phase III such as:
Download the slides from this podcast at: https://www.clinicaloptions.com/internal-medicine/programs/2019-nash-hot-topics/emerging-treatment-approaches/slides
See more NASH topics at: https://www.clinicaloptions.com/internal-medicine/programs/2019-nash-hot-topics
Professor of Hepatology
University of Birmingham
Birmingham, United Kingdom
Scientific Director
This program has been made available online.
American Gastroenterological Association (AGA)
4930 Del Ray Avenue
Bethesda, MD 20814
Phone: (301) 654-2055
Fax: (301) 654-5920
Email: member@gastro.org
Hear Brent A. Neuschwander-Tetri, MD, explore NASH screening and the interplay among NAFLD, metabolic syndrome, CV risk, and diabetes risk from CCO
Brent A. Neuschwander-Tetri, MD
Released: July 7, 2020
Hear Philip Newsome, PhD FRCPE, discuss available approaches to managing NASH: lifestyle, vitamin E, compounds that target insulin resistance from CCO
Philip N. Newsome, PhD, FRCPE
Released: July 2, 2020
Expert commentary on prevention and emerging treatment strategies for the COVID-19 pandemic from CCO
Daniel R. Kuritzkes, MD
Released: March 19, 2020
Interactive on-demand Webcast from CCO featuring expert discussion on managing patients at risk for recurrent hepatic encephalopathy
Terry D. Box, MD
Physicians:
maximum of 0.75 AMA PRA Category 1 Credits™
Released: March 17, 2020
Expired:
March 16, 2021
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.